J&J says its psoriasis drug superior to Novartis' in study


Johnson & Johnson said its drug Tremfya was found to be more effective than a rival medicine from Novartis AG in reducing the severity and affected area in adults with moderate-to-severe plaque psoriasis in a late-stage study. REUTERS: Johnson & Johnson said its drug, Tremfya, was found to be more effective than a rival medicine from Novartis AG in reducing the severity and affected area in adults with moderate-to-severe plaque psoriasis in a late-stage study.



from Biotech News